Robert Hong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert Hong has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Shahbudin H. Rahimtoola
5 shared publicationsAnil K. Bhandari
Department of Medicine, Los Angeles County/University of Southern California Medical Center
4 shared publicationsCheryl Leon
3 shared publicationsA K Bhandari
Department of Medicine, LAC-USC Medical Center
2 shared publications- Christian G. Fritz
Department of Otorhinolaryngology – Head & Neck Surgery, University of Pennsylvania, Philadelphia, PA
2 shared publications Ronald Petersen
2 shared publications
Latest Publications
- Open Access
- 1 October 2023
- Published by Wolters Kluwer Health in Current Opinion in Otolaryngology & Head and Neck Surgery
- Vol. 31 (5)
Editorial introductions
- 1 October 2023
- Published by Wolters Kluwer Health in Current Opinion in Otolaryngology & Head and Neck Surgery
- Vol. 31 (5)
Open AccessEditorial introductions
- 19 May 2023
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 138 (3) , 258-264
Quantifying the effect of shoulder size on operation duration: an analysis of stapes surgery outcomes
- 19 May 2023
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 138 (3) , 258-264
Quantifying the effect of shoulder size on operation duration: an analysis of stapes surgery outcomes
- 10 May 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (6) , S262-S263
Gene Editing/Gene Therapies: COMPREHENSIVE ANALYSIS OF THE EDITING WINDOW OF TALE BASE EDITORS
- 10 May 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (6) , S262-S263
Gene Editing/Gene Therapies: COMPREHENSIVE ANALYSIS OF THE EDITING WINDOW OF TALE BASE EDITORS
- 30 January 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 169 (2) , 358-366
Twelve‐Month Outcomes of Simultaneous Translabyrinthine Resection and Cochlear Implantation
Objective: Audiometric outcomes at 12 months following simultaneous translabyrinthine (TL) resection of vestibular schwannoma (VS) and cochlear implantation (CI).Study Design: Prospective cohort study.Setting: Tertiary referral center.Methods: Adult patients undergoing TL resection of sporadic, unilateral VS ≤ 2 cm were prospectively enrolled. Preoperative testing included binaural AZBio in noise and quiet and unilateral Consonant‐Nucleus‐Consonant (CNC). Tinnitus Handicap Index (THI) and Speech, Spatial, and Qualities of Hearing (SSQ) questionnaires were also completed. Patients underwent TL resection with simultaneous CI. The preoperative test battery was repeated at 1, 3, 6, and 12 months after activation. Statistical analysis was performed to characterize short‐term outcomes (preoperative to 3 months), longer‐term outcomes (3‐12 months), and overall changes during the preoperative to 12‐month period.Results: AZBio, CNC, and THI improved at 3 months with no significant changes thereafter and showed durable improvement at 12 months compared to preoperative testing. While SSQ did not improve at 12 months, a subset of patients showed either recovery or improvement of SSQ‐spatial subscores. Patients with cerebellopontine angle tumors had poorer performance, although the impact of tumor size and location could not be deduced based on the small sample size.Conclusion: Patients undergoing simultaneous CI and TL resection of VS had durable improvements in speech perception and tinnitus severity 12 months following surgery. Subjective improvements in localization were not observed. Additional studies are needed to determine which VS patients are optimal candidates for CI.
- 30 January 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 169 (2) , 358-366
Twelve‐Month Outcomes of Simultaneous Translabyrinthine Resection and Cochlear Implantation
Objective: Audiometric outcomes at 12 months following simultaneous translabyrinthine (TL) resection of vestibular schwannoma (VS) and cochlear implantation (CI).Study Design: Prospective cohort study.Setting: Tertiary referral center.Methods: Adult patients undergoing TL resection of sporadic, unilateral VS ≤ 2 cm were prospectively enrolled. Preoperative testing included binaural AZBio in noise and quiet and unilateral Consonant‐Nucleus‐Consonant (CNC). Tinnitus Handicap Index (THI) and Speech, Spatial, and Qualities of Hearing (SSQ) questionnaires were also completed. Patients underwent TL resection with simultaneous CI. The preoperative test battery was repeated at 1, 3, 6, and 12 months after activation. Statistical analysis was performed to characterize short‐term outcomes (preoperative to 3 months), longer‐term outcomes (3‐12 months), and overall changes during the preoperative to 12‐month period.Results: AZBio, CNC, and THI improved at 3 months with no significant changes thereafter and showed durable improvement at 12 months compared to preoperative testing. While SSQ did not improve at 12 months, a subset of patients showed either recovery or improvement of SSQ‐spatial subscores. Patients with cerebellopontine angle tumors had poorer performance, although the impact of tumor size and location could not be deduced based on the small sample size.Conclusion: Patients undergoing simultaneous CI and TL resection of VS had durable improvements in speech perception and tinnitus severity 12 months following surgery. Subjective improvements in localization were not observed. Additional studies are needed to determine which VS patients are optimal candidates for CI.
- Open Access
New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2019
Objective: To review new devices and drugs relevant to otolaryngology–head and neck surgery that were approved by the US Food and Drug Administration (FDA) in 2019.Data Sources: Approval notifications for 2019 were extracted from the ENT (ear, nose, and throat) and general and plastic surgery sections of the FDA’s medical devices and therapeutics listings.Review Methods: New therapeutics and medical devices identified from the query were analyzed by members of the American Academy of Otolaryngology–Head and Neck Surgery’s Medical Devices and Drugs Committee. Technologies were assessed by 2 independent reviewers to ascertain relevance to otolaryngology, prioritized, and classified to subspecialty field with critical review based on extant scientific literature.Conclusions: Query of the FDA drug and device database returned 105 ENT devices (50 cleared, 55 with premarket approval, and 0 de novo), 543 general and plastic surgery devices (372 cleared, 170 with premarket approval, and 1 de novo), and 46 new otolaryngology‐relevant drug approvals that occurred in 2019. Advances spanned all subspecialty areas with otology predominating, primarily due to hearing‐related technologies. While scientific evidence was available for all new devices, there was significant heterogeneity in rigor of supporting scientific data.Implications for Practice: Technological and pharmaceutical innovation is an important catalyst for advances in the surgical specialties. Familiarity with new devices and therapeutics in otolaryngology–head and neck surgery ensures that clinicians keep abreast of developments with potential to improve prevailing standards of care.
Open AccessNew Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review of 2019
Objective: To review new devices and drugs relevant to otolaryngology–head and neck surgery that were approved by the US Food and Drug Administration (FDA) in 2019.Data Sources: Approval notifications for 2019 were extracted from the ENT (ear, nose, and throat) and general and plastic surgery sections of the FDA’s medical devices and therapeutics listings.Review Methods: New therapeutics and medical devices identified from the query were analyzed by members of the American Academy of Otolaryngology–Head and Neck Surgery’s Medical Devices and Drugs Committee. Technologies were assessed by 2 independent reviewers to ascertain relevance to otolaryngology, prioritized, and classified to subspecialty field with critical review based on extant scientific literature.Conclusions: Query of the FDA drug and device database returned 105 ENT devices (50 cleared, 55 with premarket approval, and 0 de novo), 543 general and plastic surgery devices (372 cleared, 170 with premarket approval, and 1 de novo), and 46 new otolaryngology‐relevant drug approvals that occurred in 2019. Advances spanned all subspecialty areas with otology predominating, primarily due to hearing‐related technologies. While scientific evidence was available for all new devices, there was significant heterogeneity in rigor of supporting scientific data.Implications for Practice: Technological and pharmaceutical innovation is an important catalyst for advances in the surgical specialties. Familiarity with new devices and therapeutics in otolaryngology–head and neck surgery ensures that clinicians keep abreast of developments with potential to improve prevailing standards of care.
- 29 July 2019
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 20, 1120-1123
Rheumatoid Arthritis and Cardiac Compression Caused by a Large Fibrotic Intrapericardial Mass and Effusion: A Case Report
BACKGROUND:Pericarditis is common in rheumatoid arthritis, mostly occurring as an extra-articular manifestation of the disease. We describe a patient with stable rheumatoid arthritis who presented with a large pericardial effusion and a compressive fibrotic pericardial mass. The patient had recently started treatment with a tumor necrosis factor-alpha (TNF-α) antagonist. CASE REPORT:The patient was a 58-year-old woman with rheumatoid arthritis who presented with right ventricular compression caused by a pericardial fibrotic mass and a large pericardial effusion. The patient did not have active arthritis at the time of presentation. She had been started on treatment with a tumor necrosis factor-alpha (TNF-α) antagonist 4 months prior to this presentation. She was successfully treated with surgical pericardiectomy and resection of the pericardial mass. Pathologic analysis of the pericardial mass demonstrated fibrosis and no evidence of active inflammation, rheumatoid arthritis, opportunistic infection, or malignancy. CONCLUSIONS:We describe a patient with stable rheumatoid arthritis who developed subacute right heart compression syndrome secondary to pericardial effusion and fibrous pericardial mass. The exact cause of pericarditis and the pericardial mass remain uncertain. There is a need for increased awareness of the association between use of TNF-α antagonists and the possible development of an intrapericardial fibrotic mass and effusion.
- 29 July 2019
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 20, 1120-1123
Rheumatoid Arthritis and Cardiac Compression Caused by a Large Fibrotic Intrapericardial Mass and Effusion: A Case Report
BACKGROUND:Pericarditis is common in rheumatoid arthritis, mostly occurring as an extra-articular manifestation of the disease. We describe a patient with stable rheumatoid arthritis who presented with a large pericardial effusion and a compressive fibrotic pericardial mass. The patient had recently started treatment with a tumor necrosis factor-alpha (TNF-α) antagonist. CASE REPORT:The patient was a 58-year-old woman with rheumatoid arthritis who presented with right ventricular compression caused by a pericardial fibrotic mass and a large pericardial effusion. The patient did not have active arthritis at the time of presentation. She had been started on treatment with a tumor necrosis factor-alpha (TNF-α) antagonist 4 months prior to this presentation. She was successfully treated with surgical pericardiectomy and resection of the pericardial mass. Pathologic analysis of the pericardial mass demonstrated fibrosis and no evidence of active inflammation, rheumatoid arthritis, opportunistic infection, or malignancy. CONCLUSIONS:We describe a patient with stable rheumatoid arthritis who developed subacute right heart compression syndrome secondary to pericardial effusion and fibrous pericardial mass. The exact cause of pericarditis and the pericardial mass remain uncertain. There is a need for increased awareness of the association between use of TNF-α antagonists and the possible development of an intrapericardial fibrotic mass and effusion.
- 1 July 2019
- Vol. 78 (7) , 223-229
Lymphocytic Myocarditis and Cardiogenic Shock in Hawai'i: A Case Series.
Lymphocytic myocarditis is an inflammatory disease of the heart that may present in a myriad of fashions ranging from mild febrile illness to florid myocarditis and cardiogenic shock. Given its nonspecific clinical presentation, the diagnosis of lymphocytic myocarditis is often challenging. The authors describe four cases of lymphocytic myocarditis in young women who presented with cardiogenic shock. Two patients survived and two died. This presentation has not been seen previously in Hawai'i and the public awareness of this condition is critical. Early diagnosis and the prompt initiation of biventricular mechanical circulatory support appear to have been critical in improving patient survival.
- 1 July 2019
- Vol. 78 (7) , 223-229
Lymphocytic Myocarditis and Cardiogenic Shock in Hawai'i: A Case Series.
Lymphocytic myocarditis is an inflammatory disease of the heart that may present in a myriad of fashions ranging from mild febrile illness to florid myocarditis and cardiogenic shock. Given its nonspecific clinical presentation, the diagnosis of lymphocytic myocarditis is often challenging. The authors describe four cases of lymphocytic myocarditis in young women who presented with cardiogenic shock. Two patients survived and two died. This presentation has not been seen previously in Hawai'i and the public awareness of this condition is critical. Early diagnosis and the prompt initiation of biventricular mechanical circulatory support appear to have been critical in improving patient survival.
- 1 January 2015
- Vol. 74 (1) , 16-20
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.
Recent efforts directed at potential litigation in Hawai'i have resulted in a renewed interest for genetic screening for cytochrome P450 2C19 (CYP2C19) polymorphisms in patients treated with clopidogrel. Clopidogrel is an antiplatelet agent, frequently used in combination with aspirin, for the prevention of thrombotic complications with acute coronary syndrome and in patients undergoing percutaneous coronary interventions. Cytochrome P-450 (CYP) 2C19 is an enzyme involved in the bioactivation of clopidogrel from a pro-drug to an active inhibitor of platelet action. Patients of Asian and Pacific Island background have been reported to have an increase in CYP2C19 polymorphisms associated with loss-of-function of this enzyme when compared to other ethnicities. This has created an interest in genetic testing for CYP2C19 polymorphisms in Hawai'i. Based upon our review of the current literature, we do not feel that there is support for the routine screening for CYP2C19 polymorphisms in patients being treated with clopidogrel; furthermore, the results of genetic testing may not be helpful in guiding therapeutic decisions. We recommend that decisions on the type of antiplatelet treatment be made based upon clinical evidence of potential differential outcomes associated with the use of these agents rather than on the basis of genetic testing.
- 1 January 2015
- Vol. 74 (1) , 16-20
Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.
Recent efforts directed at potential litigation in Hawai'i have resulted in a renewed interest for genetic screening for cytochrome P450 2C19 (CYP2C19) polymorphisms in patients treated with clopidogrel. Clopidogrel is an antiplatelet agent, frequently used in combination with aspirin, for the prevention of thrombotic complications with acute coronary syndrome and in patients undergoing percutaneous coronary interventions. Cytochrome P-450 (CYP) 2C19 is an enzyme involved in the bioactivation of clopidogrel from a pro-drug to an active inhibitor of platelet action. Patients of Asian and Pacific Island background have been reported to have an increase in CYP2C19 polymorphisms associated with loss-of-function of this enzyme when compared to other ethnicities. This has created an interest in genetic testing for CYP2C19 polymorphisms in Hawai'i. Based upon our review of the current literature, we do not feel that there is support for the routine screening for CYP2C19 polymorphisms in patients being treated with clopidogrel; furthermore, the results of genetic testing may not be helpful in guiding therapeutic decisions. We recommend that decisions on the type of antiplatelet treatment be made based upon clinical evidence of potential differential outcomes associated with the use of these agents rather than on the basis of genetic testing.
- 1 June 2014
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 6 (2) , 389
Comments: Defining the Scholarly and Scholarship Common Program Requirements
- 1 June 2014
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 6 (2) , 389
Comments: Defining the Scholarly and Scholarship Common Program Requirements
- Open Access
- 27 August 2013
- Published by Wiley in Clinical Cardiology
- Vol. 36 (12) , 737-742
Methamphetamine‐Associated Cardiomyopathy
Methamphetamine and related compounds are now the second most commonly used illicit substance worldwide, after cannabis. Reports of methamphetamine‐associated cardiomyopathy (MAC) are increasing, butMAChas not been well reviewed. This analysis ofMACwill provide an overview of the pharmacology of methamphetamine, historical perspective and epidemiology, a review of case and clinical studies, and a summary of the proposed mechanisms forMAC. Clinically, many questions remain, including the appropriate therapeutic interventions forMAC, the incidence and prevalence of cardiac pathology in methamphetamine users, risk factors for developingMAC, and prognosis of these patients. In conclusion, recognition of the significance ofMACamong physicians and other medical caregivers is important given the growing use of methamphetamine and related stimulants worldwide.
- 27 August 2013
- Published by Wiley in Clinical Cardiology
- Vol. 36 (12) , 737-742
Open AccessMethamphetamine‐Associated Cardiomyopathy
Methamphetamine and related compounds are now the second most commonly used illicit substance worldwide, after cannabis. Reports of methamphetamine‐associated cardiomyopathy (MAC) are increasing, butMAChas not been well reviewed. This analysis ofMACwill provide an overview of the pharmacology of methamphetamine, historical perspective and epidemiology, a review of case and clinical studies, and a summary of the proposed mechanisms forMAC. Clinically, many questions remain, including the appropriate therapeutic interventions forMAC, the incidence and prevalence of cardiac pathology in methamphetamine users, risk factors for developingMAC, and prognosis of these patients. In conclusion, recognition of the significance ofMACamong physicians and other medical caregivers is important given the growing use of methamphetamine and related stimulants worldwide.